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Abstract
Low-grade intestinal inflammation plays a key role in 
the pathophysiology of irritable bowel syndrome (IBS), 
and this role is likely to be multifactorial. The aim of this 
review was to summarize the evidence on the spectrum 
of mucosal inflammation in IBS, highlighting the 
relationship of this inflammation to the pathophysiology 
of IBS and its connection to clinical practice. We carried 
out a bibliographic search in Medline and the Cochrane 
Library for the period of January 1966 to December 
2014, focusing on publications describing an interaction 
between inflammation and IBS. Several evidences 
demonstrate microscopic and molecular abnormalities 
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Inflammation in irritable bowel syndrome: Myth or new 
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in IBS patients. Understanding the mechanisms 
underlying low-grade inflammation in IBS may help to 
design clinical trials to test the efficacy and safety of 
drugs that target this pathophysiologic mechanism.
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Core tip: Low-grade intestinal inflammation plays 
a key role in the pathophysiology of irritable bowel 
syndrome, and this influence is likely multifactorial. 
Several evidences showed microscopic and molecular 
abnormalities in large subsets of patients with irritable 
bowel syndrome. Understanding the mechanisms 
underlying the low-grade inflammation in this disease 
may help to design clinical trials to test the efficacy 
and safety of drugs that target this pathophysiologic 
mechanism.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic, relapsing, 
and remitting functional disorder of the gastrointestinal 
tract characterized by abdominal pain, bloating, and 
changes in bowel habits that lack a known structural 
or anatomic explanation[1].
IBS consists of a set of altered bowel habits over 
a period of time and includes abdominal pain and 
discomfort. IBS is one of the most common diagnoses 
in primary care, accounting for approximately 12% 
of all visits[2]. In addition, a survey conducted by 
Russo et al[3] found IBS to be the most common 
functional gastrointestinal diagnosis, comprising 35% 
of all outpatient referrals to gastroenterologists[2,3]. 
Therefore, IBS is also the most common diagnosis 
for gastroenterologists, accounting for 20%-50% of 
patient visits[2,4].
With regard to the sex-related prevalence of IBS, 
in Western countries, the prevalence of IBS in female 
patients outnumbers that in male patients by 2:1[5,6]. 
Furthermore, the ratio of female to male IBS sufferers 
in the non-patient population is 2:1, and within the 
patient population who seek consultations with primary 
care physicians, females outnumber male patients by 
3:1[5,7]. Finally, in tertiary-care settings, the number of 
female IBS patients is four- to five-times higher than 
the number of males[5-8]. This prevalence should not 
only be strictly attributed to sex, but also to gender-
related differences in healthcare-seeking behavior 
and sociocultural characteristics that vary between 
men and women with IBS as well as among different 
cultures[5,6]. 
According to the Rome Ⅲ criteria, IBS is defined 
based on the presence of recurrent abdominal pain 
or discomfort at least three days per month in the 
past three months associated with two or more of the 
following: (1) improvement with defecation; (2) onset 
associated with a change in frequency of stool; and (3) 
onset associated with a change in form (appearance) 
of stool. These criteria should be fulfilled for the 
previous three months with symptom onset at least six 
months before diagnosis[9].
Rome Ⅲ criteria subtype IBS according to the 
predominant bowel habit as IBS with constipation 
(IBS-C), IBS with diarrhea (IBS-D), mixed type, and 
unclassified[9]. To this end, the definition of bowel-
habit type is based on the patient’s description of the 
stool form by referring to the Bristol Stool Scale[10]. 
Furthermore, IBS patients can be divided into two 
categories: sporadic (nonspecific) and postinfectious 
(PI-IBS) inflammatory bowel disease-associated[11,12].
IBS symptoms cannot be explained by structural 
abnormalities, and specific laboratory tests or bio-
markers are not available for IBS. Therefore, IBS is 
classified as a functional disorder whose diagnosis 
depends on the history of manifested symptoms[13].
The cause of IBS is unknown, but a single factor is 
not likely to be responsible for the several presentations 
of this complex disorder[1]; new fields of research in this 
area include mucosal inflammation, postinfectious low-
grade inflammation, genetic and immunologic factors, 
alteration of the human microbiota, alterations of the 
intestinal permeability, and dietary and neuroendocrine 
factors[13]. Usually, routine histologic examinations do 
not show significant colonic mucosal abnormalities 
in the majority of IBS patients; however, recent 
quantitative histologic, immunohistochemical, and 
ultrastructural analyses have indicated subtle organic 
alterations in these patients. 
This literature review aims to summarize the findings 
relating the spectrum of mucosal inflammation to IBS, 
highlighting their relationship to the pathophysiology of 
IBS and their connections, if any, to clinical practice.
RESEARCH
We carried out a bibliographic search in MEDLINE for 
the period of January 1966 to July 2015, and focused 
on identifying publications describing an interaction 
between inflammation and IBS. The keywords used 
were: irritable bowel syndrome, inflammation, mucosal 
inflammation, pathology, mast cells, neuroendocrine 
cells, immune cells, intestinal permeability, and enteric 
nerves. The inclusion criteria to select articles were 
based on design (systematic reviews, meta-analysis, 
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clinical trials, and experimental studies on animals) 
and population (adult patients > 18 years of age). We 
excluded articles not pertinent to this topic.
According to the aforementioned criteria, we found 
305 studies, and we excluded 100 studies because 
they were not pertinent to this topic (Figure 1).
ROLE OF ENDOSCOPY IN IBS
According to the American Gastroenterology Association, 
“a colonoscopy is recommended for patients over 
age 50 years (due to higher pretest probability of 
colon cancer), but in younger patients, performing a 
colonoscopy or sigmoidoscopy is determined by clinical 
features suggestive of disease (e.g., diarrhea, weight 
loss), and may not be indicated”[14].
However, the British guidelines suggest that, “given 
the high frequency of colonic cancer in the population 
at large, an examination of the colon is advisable 
for a change in bowel habit over the age of 50”; the 
authors of these guidelines highlighted that, “as IBS 
patients have no increased risk of colon cancer, advice 
on screening for this is no different from the general 
population”[15].
More recently, Japanese guidelines suggested 
that “colonoscopy has a diagnostic value, not only for 
excluding organic diseases but also for supporting the 
existence of pathophysiology compatible to IBS due 
to visceral hypersensitivity to colonoscopic procedures 
and colonic spasms”[16].
A prospective, multicenter study performed by 
Ishihara and coworkers[17] aimed to determine the 
presence of organic colonic lesions in IBS patients. 
Their study showed that the prevalence of organic 
colonic diseases in IBS patients was at an acceptably 
low level, thus showing that the Rome Ⅲ criteria 
are specific for the diagnosis of IBS. Conversely, 
another study performed by Hsiao and coworkers[18] 
demonstrated that IBS was not associated with the 
development of colon cancer in Taiwan.
Despite these recommendations, a recent Korean 
survey indicated that colonoscopy was the most 
commonly required test (79.5%) in IBS patients[19], 
whereas a study performed by Lieberman and 
coworkers[20] to evaluate trends in the utilization and 
outcomes of colonoscopy in the United States from 
2000 to 2011 showed that the most common reason 
for colonoscopy in patients aged < 50 years was 
the evaluation of symptoms, such as IBS (28.7%), 
together with bleeding or anemia (35.3%).
Based on these updated data, IBS still represents the 
majority of colonoscopic biopsies seen by pathologists[21] 
that are usually considered either normal or near to 
normal on routine histologic examination. These findings 
provide valuable information to the physician who is 
suspecting a diagnosis of IBS. However, the pathologists 
must be aware of variations in normal tissue as well 
as artifacts that may result from bowel preparations 
or the biopsy procedure in order to not to report these 
variations as abnormal. Furthermore, the pathologists 
must consider subtle morphologic changes reported in 
the intestinal mucosa in IBS and associated with chronic 
inflammatory cells, mast cells, enteroendocrine cells, 
and enteric nerves[22].
INFLAMMATION IN IBS
The intestinal mucosa harbors a florid immune system 
that can be regarded as “physiologically inflamed”[23]. 
Thus low-grade inflammation can only be evaluated 
using quantitative assessments[24]. IBS patients have 
been shown to exhibit significant increases in lamina 
propria immune cells in the colonic mucosa compared 
with healthy subjects, which appears to be more 
predominant in the right than in the left colon[25].
Granulocytes and plasma cells 
More than ten years ago, O’Sullivan et al[26] evaluated 
the number of plasma cells, lymphocytes, eosinophils, 
neutrophils, and macrophages in a case-control study. 
Specifically, each cell type was semiquantitatively 
graded in hematoxylin-and-eosin-stained sections of 
the entire colon, and possible increases in the number 
of mast cells (MCs) in the colon of IBS patients 
compared with controls were examined using a 
monoclonal mouse antibody for human MC tryptase 
(AA1). Other than MCs, increases in cellular infiltrate 
were not observed in the IBS group, and the number 
of MCs was significantly increased in the cecum of IBS 
patients compared with controls.
Similarly, in 2008, Piche and coworkers[27] aimed to 
examine associations between fatigue, depression, and 
the MCs of the colonic mucosa in IBS by comparing the 
numbers of CD3-positive intraepithelial T lymphocytes, 
MCs, plasma cells, eosinophils, and neutrophils in cecal 
biopsies taken during colonoscopy. There was not a 
significant difference in the numbers of intraepithelial 
lymphocytes, plasma cells, eosinophils, or neutrophils 
between IBS patients and healthy controls, but the MC 
numbers per high-power field were significantly higher 
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Figure 1  Literature findings on the relationship between irritable bowel 
syndrome and inflammation (n = 305).
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in IBS patients in the rectum[35,36], rectosigmoid 
colon[37,38], descending colon[39-44], ascending colon[36], 
cecum[45], terminal ileum[25,36,46], jejunum[47-49], and 
duodenum[29,50] (Figure 2).
However, discrepancies in data obtained from 
these studies could be due to sex-specific differences, 
bowel preparation artifacts, fixation protocols, tissue 
orientation, sample size, or IBS-related recruitment 
criteria[32,43,44,51]. Furthermore, clinical studies have also 
yielded conflicting evidence correlating MC numbers 
with the onset of abdominal pain[32].
The number of functionally active MCs (exhibiting 
changes in the release of tryptase and histamine), 
rather than the absolute number of MCs, plays a 
pivotal role in IBS[43,50]. Consequently, the role of MCs 
in IBS may be affected by cells that are functionally 
active and form close connections with enteric and 
extrinsic nerve terminals, thus determining visceral 
hypersensitivity and altered gut function[47].
Lymphocytes 
The aforementioned inflammatory changes described 
in the mucosa of IBS patients show that immune 
activation may play a role in IBS pathophysiology[34]. 
Mucosal T- and B-type lymphocytes are also part of 
the gut adaptive immune response to pathogens[32]. 
An increased density of T lymphocytes in the 
mucosa of IBS patients has been widely demonstrated. 
Specifically, the T-cell density is higher in the 
rectum[35,36,52], rectosigmoid colon[53], colon[38,48,54], 
cecum[26], jejunum[55], and duodenum[56]. Like for MCs, 
several studies showed that IBS patients exhibit a 
normal lymphocyte density in different intestinal tissue 
segments[19,36,38,53,57-61]. These discrepancies may be 
due to differences in the immunostaining techniques, 
quantification methods, and IBS-related recruitment 
criteria (Figure 3)[32].
Conversely, the density of B-cells in the rectum[19,36], 
colon[19,43,53,62], cecum[19,20], ileum[36], or jejunum[60] 
did not differ in IBS patients. However, Forshammar 
and coworkers[62] and others[32] found a decrease in 
secretory B cells in the colon (Figure 4).
in IBS patients than in healthy controls (9.3 vs 4.0, P 
= 0.001). Furthermore, the number of MCs correlated 
with the severity of fatigue and depression scores in 
IBS patients but not in healthy controls[28].
With regard to the small bowel, Walker et al[29] 
examined the MC, eosinophil, and intraepithelial 
lymphocyte populations in duodenal biopsies of 
subjects with IBS and functional dyspepsia. Their 
study showed a significant increase in the number 
of intraepithelial lymphocytes in biopsies from the 
duodenum in patients with IBS-C. However, this 
increase was not observed in the second part of the 
duodenum. Nevertheless, MC counts were also higher 
in IBS cases in both the first and second parts of the 
duodenum, but this difference was only significant for 
constipation-predominant IBS[28]. Interestingly, the 
eosinophil counts in this study did not differ between 
IBS patients and controls in either the first or second 
part of the duodenum[28].
To date, a significant difference in the numbers 
of plasma cells, neutrophils, or eosinophils has not 
been demonstrated among IBS cases[28]. Importantly, 
increases in eosinophils were not identified in IBS, 
but the eosinophil counts were elevated in individuals 
with functional dyspepsia[29]. Functional dyspepsia 
and IBS demonstrate significant overlap in cross-
sectional surveys[30], despite attempts to classify them 
separately, and a biomarker to predict the presence of 
IBS remains elusive[31]. Therefore, this histopathologic 
marker may serve to distinguish the two conditions[28].
MCs
MCs are innate immune cells involved in food allergies, 
wound healing, and protection against pathogens[32]. 
Their functional activation consists of a degranulation 
process, leading to the release of various compounds, 
such as histamine, tryptase, and chymase[32].
More than 40 years ago, Hiatt and Katz[33] were 
the first to demonstrate MC infiltration in the muscular 
layer of full-thickness colonic biopsy samples from 
four patients with “spastic colitis”[34]. Increases in 
the number of mucosal MCs have been observed 
Figure 2  Immunohistochemistry for tryptase showing increases in the number of mast cells in the colonic mucosa in inflammatory bowel disease. A: 
Irritable bowel syndrome patient; B: Control (× 40 magnification). Courtesy of Giancarlo Pompei, personal data.
A B
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With regard to intraepithelial lymphocytes, several 
discrepancies have been reported in studies assessing the 
density of these cells in IBS patients. An increase in density 
has been demonstrated in the rectum[35,36,57], colon[57], 
jejunum[55,49], and duodenum[56], but these increases were 
not confirmed by other groups[20,32,45,49,59,61].
Dendritic cells and macrophages 
Dendritic cells are antigen-presenting cells that are 
usually located at the surveillance interfaces of the 
human body, such as the skin or mucosa, and play a 
pivotal role in the generation and regulation of immune 
responses[63]. In fact, they represent the link between 
allergen uptake and the clinical manifestations of 
intestinal inflammation[64,65]. Furthermore, the gut 
also harbors abundant macrophages. These cells 
do not function as typical antigen-presenting cells 
and lack the cellular machinery for the production of 
pro-inflammatory cytokines and induction of potent 
adaptive immune responses. However, they show very 
potent phagocytic activity[65].
In a Trichinella spiralis mouse model of PI-IBS, 
Long and coworkers[66] reported numerical and 
phenotypic alterations in the lamina propria dendritic 
cells following acute T. spiralis infection. In their study, 
the lamina propria dendritic cells expressed increased 
levels of costimulatory molecules and exhibited a 
greater ability to migrate and induce CD4+ T-cell 
proliferation[66]. Consequently, these changes favored 
increased levels of pro-inflammatory interferon-γ, 
interleukin-23, and tumor necrosis factor-α production 
in the so-called “PI-IBS stage”[66,67].
With regard to macrophages, the numbers of 
resident CD68+ macrophages are reduced in PI-
IBS cases following Campylobacter jejuni infection, 
probably due to the cytotoxic nature of the pathogen 
inside host cells[50]. Similarly, Shigella spp.[68,69] and 
Salmonella infections have also been shown to be 
involved in PI-IBS, and both of these organisms are 
intracellular pathogens that induce phagocytosis by 
macrophages[70,71]. Furthermore, Salmonella seems 
to be less cytotoxic to macrophages[72] and also 
causes a marked interleukin-18 response[72] with 
important implications in exerting paracrine effects 
on surrounding immune cells (inducing interferon-γ 
expression). These changes result in increased levels 
of activated T cells in the infected intestine[47,52,54,55,57].
Enteroendocrine cells
Enteroendocrine cells (residing among the epithelial 
Figure 3  Immunohistochemistry for CD3 showing increase in the number of intraepithelial T-lymphocytes in the large bowel in inflammatory bowel 
disease. A: Irritable bowel syndrome patient; B: Normal distribution of T-lymphocytes, which are mainly distributed within the lamina propria of the large bowel of a 
control patient (× 20 magnification). Courtesy of Giancarlo Pompei, personal data.
A B
A B
Figure 4  Immunohistochemical staining for CD20. An equivalent distribution of B lymphocytes in the lamina propria was seen in the large intestine. A: Patient with 
irritable bowel syndrome; B: Control patient (× 20 magnification). Courtesy of Giancarlo Pompei, personal data.
Sinagra E et al . Inflammation in IBS
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cells of the mucosa in all gut segments, with the 
exception of the esophagus) secrete multiple 
regulatory molecules that control several functions, 
such as postprandial secretion and motility[12,73,74]. 
Animal experimental studies have demonstrated 
abnormalities in the function of enteroendocrine 
cells in the setting of gastrointestinal infection[73]. 
Enteroendocrine cells seem to be involved in visceral 
hypersensitivity, disturbed gastrointestinal motility, 
and abnormal gut secretion[12] that patients with IBS 
usually present[75-77].
In fact, visceral hypersensitivity has been shown 
in the colon of IBS patients[78-85], but the correlation 
of this disturbance with the severity of abdominal 
pain is currently poorly understood[12]. Some 
authors hypothesize the involvement of a peripheral 
mechanism in visceral hypersensitivity in IBS[86-88]. 
Because the gut mucosa can produce high levels 
of serotonin[88], a reduction in serotonin impairs 
intracellular uptake and degradation in the gut 
epithelial cells and consequently increases serotonin 
availability of in the gut mucosa[89-92]. Therefore, 
the amount of serotonin available at its receptors is 
markedly increased[12,87,88]. Due to this mechanism, 
the development of visceral hypersensitivity in PI-IBS 
patients may be due to the increase in serotonin at 
the 5-hydroxytryptamine 3 receptors of the sensory 
neurons of the enteric nervous system.
Dysmotility has also been shown in the small 
and large bowel of IBS patients, as evidenced by 
the involvement of cholecystokinin, ghrelin, secretin, 
serotonin, and peptide YY[12]. Both esophageal 
motility abnormalities and abnormal gastric emptying 
have been observed in IBS patients with conflicting 
results[93-108]. Specifically, IBS-C patients exhibit 
delayed gastric emptying, whereas accelerated 
gastric emptying was observed in IBS-D patients[77,98]. 
In this setting, ghrelin was shown to stimulate 
gastric and small- and large-bowel motility[106-117]. 
Conversely, serotonin relaxes the stomach through 
a nitrergic pathway and consequently delays gastric 
emptying[118-120]. Moreover, cholecystokinin[121-123] 
and secretin[124,125] were shown to relax the proximal 
stomach, which inhibited gastric emptying in a manner 
similar to secretin; furthermore, small-bowel transit 
was also found to be delayed overall in IBS-C patients 
and accelerated in IBS-D patients[126-131], but conflicting 
results have been reported[132-139]. 
Ghrelin, which is involved in the stimulation of 
small-bowel motility, and peptide YY, a regulator of 
the ileal brakes[140-145], play pivotal roles in gastric 
emptying by stimulating the absorption of water 
and electrolytes and inhibiting prostaglandin E2 and 
vasoactive intestinal polypeptide[146-148]. Therefore, 
ghrelin cell density is reportedly low in the stomach, 
and that of peptide YY is reported to be high in the 
ileal mucosa of IBS-C patients, whereas the ghrelin cell 
density is reported to be high in the stomach, and that 
of secretin is reported to be low in the duodenum of 
IBS-D patients[12]. Furthermore, colorectal transit was 
found to be delayed in IBS-C patients and accelerated 
in IBS-D patients[80,125,126,149-154], but contradictory 
results have been reported[12,105,152,154-176].
Finally, abnormal gastrointestinal secretion is 
common in IBS patients. Among the abnormalities 
in the enteroendocrine cells in IBS patients, low 
levels of duodenal cholecystokinin (which stimulates 
the secretion of digestive enzymes from pancreatic 
exocrine glands) and secretin (which stimulates 
pancreatic bicarbonate and fluid secretions)[122,123], as 
well as high levels of ileal peptide YY (which stimulates 
the absorption of water and electrolytes), were 
reported in IBS-C patients[12].
Intestinal permeability 
The term “mucosal barrier” was adopted by Cummings 
et al[177] in 2004 to describe “the complex structure 
that separates the internal milieu from the luminal 
environment, consisting of the vascular endothelium, 
the epithelial cell lining, and the mucus layer, next to 
which digestive secretions, immune molecules, cell 
products such as cytokines, inflammatory mediators, 
and antimicrobial peptides, are found, mainly produced 
by Paneth cells in the crypts of the small intestine”[177,178].
Conversely, impaired intestinal permeability is 
defined as “an altered permeability being nontransiently 
changed compared to the normal permeability 
leading to a loss of intestinal homeostasis, functional 
impairments and disease”[178]. Increases in the numbers 
of MCs in the gut of IBS patients were found to be 
related to changes in gut permeability[32,179-181]. In 
IBS patients, the assessment of permeability via the 
urinary recovery of orally administered markers has 
demonstrated increases in the permeability of the small 
and in the large bowels[45,182-184], but results have been 
contradictory[185-187]. Furthermore, rectal permeability 
was also reportedly increased in IBS-D patients 
following exposure to MC tryptase[188]. Finally, recent 
studies of the permeability of the epithelial barrier have 
reported a decrease in the colonic expression of the 
tight junction proteins occludin, claudin-1, and zonula 
occludens-1 in IBS patients[42,189] (Figure 5).
Several aliments, as well as microbiota and 
bile acids, have been proposed to cause low-grade 
inflammation and altered permeability in IBS. In fact, 
in some patients, IBS was related to food allergy[190]. 
Furthermore, endogenous triggers, such as MC-
derived histamine, proteases, and eicosanoids, could 
increase intestinal permeability, either directly or via 
the stimulation of neurons of the enteric nervous 
system[183]. Moreover, serotonin was also identified 
as an endogenous trigger of pain, inflammation, and 
increased permeability in IBS[40]; therefore, LX1031, an 
oral inhibitor of tryptophan hydroxylase, the principal 
enzyme needed for mucosal serotonin synthesis, has 
been successful for treatment of patients with non-
Sinagra E et al . Inflammation in IBS
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constipating IBS[191].
Enteric nerves 
Few studies have investigated the role of calcitonin 
gene related peptide and substance P. Wang et al[37] 
investigated the incidence of IBS in patients who 
had recovered from bacillary dysentery by focusing 
on neuroimmunologic changes, including changes in 
interleukins, MCs, neuropeptides, and the relationship 
between MCs and intestinal nerves[50]. The density of 
substance P-immunoreactive fibers was increased in 
both the ileal and the rectosigmoid samples of IBS 
patients[37], but the density of calcitonin gene related 
peptide-containing fibers remained unchanged. 
Palsson and coworkers[192] reported similar findings, 
and Kerkhoffs and coworkers[193] reported an increase 
of rectal substance P. However, these findings have not 
been universal[192,194], possibly reflecting region-specific 
discrepancies[51].
Neuronal plasticity in the enteric nervous system 
has also been investigated[195]. Akbar et al[38] 
investigated the capsaicin receptor transient receptor 
potential vanilloid 1-immunoreactive nerve fibers in 
colonic biopsies from patients with IBS. Specifically, 
they demonstrated that the number of nerve fibers 
exhibiting immunoreactivity for substance P and 
transient receptor potential vanilloid 1 was increased in 
IBS patients. Moreover, the number of these fibers did 
not differ by IBS subtype, but significantly correlated 
with patient pain scores[50,196].
Nerve growth factor has also been suggested 
to play a central role in promoting the growth and 
differentiation of primary afferent fibers[50]. Specifically, 
its expression was found to be markedly increased 
in rectal biopsies from pediatric[197] and adult IBS 
patients[198], suggesting both the sprouting of sensory 
afferent fibers expressing transient receptor potential 
vanilloid 1 and increases in receptor sensitivity in IBS, 
which consequently induced visceral hyperalgesia[50]. 
More recently, Dothel et al[199] also showed that 
nerve fiber density and sprouting, as well as the 
expression of nerve growth and neurotrophic tyrosine 
kinase receptor type 1, are significantly increased 
in the mucosal tissues of patients with IBS. Mucosal 
mediators participate in these neuroplastic changes.
Finally, the morphology of enteric glia, which are 
known to regulate intestinal barrier integrity and 
neuronal activity[200] has only been examined in one 
study of human intestinal biopsy samples from IBS 
patients and was found to be unchanged[50,201].
CONCLUSION
Low-grade intestinal inflammation plays a key role 
in the pathophysiology of IBS, and this role is likely 
multifactorial[202]. Several studies demonstrated 
microscopic and molecular abnormalities in IBS 
patients[202,203].
The above-reported evidence provides a rationale 
to test the efficacy of intestinal anti-inflammatory 
compounds in patients with IBS. Previously, treatment 
with corticosteroids was found to be ineffective in PI-
IBS patients[204]; however, MC stabilizers have produced 
promising results, particularly in IBS-D, suggesting 
that immune mechanisms and MCs are involved in 
the generation of IBS symptoms[205,206]. Based on this 
approach, Clarke and coworkers[207] recently conducted 
a phase 3, multicenter, tertiary setting, randomized, 
double-blind, placebo-controlled trial in patients with 
Rome Ⅲ-confirmed IBS to evaluate the efficacy and 
safety of mesalazine in patients with IBS. In this study, 
mesalazine treatment was not superior to placebo 
based on the study primary endpoint (68.6% vs 
67.4%, 95%CI: 12.8-15.1, P = 0.870). However, the 
placebo response was high in this trial and this study 
enrolled both male and female subjects and patients 
with mild symptoms[207], which likely masked drug 
efficacy. Furthermore, a subgroup of patients with IBS 
showed a sustained therapy response and benefits 
from mesalazine therapy[207].
As mentioned above, abnormalities in the enteric 
nervous system of the gut may alter digestion, 
gastrointestinal motility, and visceral hypersensitivity, 
which contribute to symptom onset and play a pivotal 
A B
Figure 5  Immunohistochemistry for chromogranin A showing increased expression in nerve terminals at the level of the basal membrane in the large 
intestine in inflammatory bowel disease. A: Irritable bowel syndrome patient; B: Control patient (× 40 magnification). Courtesy of Giancarlo Pompei, personal data.
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role in the pathogenesis of IBS[12].
The enteric nervous system of the gut seems to be 
affected by genetic differences, diet, intestinal flora, 
and inflammation[12]. For example, the food content 
of FODMAPs and fibers, which interacts with the 
intestinal flora and drives subsequent fermentation, 
may increase intestinal osmotic pressure to induce 
hormonal and serotonin release[12]. Targeting these 
known factors may improve the control of IBS 
symptoms by acting on mechanisms that trigger these 
symptoms and regulate the pathophysiology of IBS. 
Finally, probiotics have also been found to be effective 
in select IBS patients, as suggested by several recent 
systematic reviews, guidelines and meta-analyses, by 
improving intestinal permeability[208-212].
In conclusion, a high proportion of IBS patients 
show low-grade inflammation, which is a multifactorial 
process, in the intestinal mucosa. Understanding the 
mechanisms underlying the low-grade inflammation 
in IBS may allow the design of clinical trials that 
test the efficacy and safety of drugs that target the 
pathophysiologic mechanism of this disease.
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